WuXi STA provides an integrated formulation development and manufacturing platform from preclinical to commercial. The integrated platform supports broad range of dosage forms, different kinds of packaging and labeling. In 2022 alone, 2,498 pre-formulation molecules were evaluated, 2,815 clinical and commercial batches manufactured, and we supported 45 late phase and commercial projects.